Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04, Zacks reports. The business had revenue of $69.11 million for the quarter, compared to analyst estimates of $61.58 million.
Esperion Therapeutics Price Performance
NASDAQ:ESPR traded up $0.10 during trading hours on Friday, reaching $1.69. 3,260,581 shares of the company traded hands, compared to its average volume of 4,053,618. Esperion Therapeutics has a 1-year low of $1.56 and a 1-year high of $3.94. The stock has a market cap of $332.99 million, a P/E ratio of -2.64 and a beta of 1.01. The firm's 50-day moving average is $1.97 and its 200-day moving average is $2.08.
Analyst Upgrades and Downgrades
Several brokerages recently commented on ESPR. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities reissued a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $6.75.
View Our Latest Analysis on Esperion Therapeutics
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
